secwatch.observer — SEC 8-K summary
======================================

Issuer:     Fulcrum Therapeutics, Inc. (FULC)
CIK:        0001680581
Form:       8-K
Filed at:   2024-09-12T23:59:59+00:00
Accession:  0001193125-24-217822
Event type: other_material
Sentiment:  negative
Materiality: 0.90
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Fulcrum Therapeutics Phase 3 losmapimod trial fails; program suspended
----------------------------------------------------------------------

- REACH trial missed primary endpoint: RSA change p=0.75 vs placebo at week 48.
- All secondary endpoints (MFI, shoulder strength, PROs) did not reach statistical significance.
- Fulcrum suspends losmapimod development; safety profile consistent with prior studies.
- $273.8M cash as of June 30 used for pociredir (SCD), DBA programs, and early discovery.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1680581/000119312524217822/0001193125-24-217822-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1680581/000119312524217822/d844807d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-217822

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer